Evidence map›Paper›PMID 34181353›Full record

ArticleAsian Pacific journal of cancer prevention : APJCP2021

Involvement of Circulating Cell-Free Mitochondrial DNA and Proinflammatory Cytokines in Pathogenesis of Chronic Obstructive Pulmonary Disease and Lung Cancer.

Olga Bulgakova, Asemgul Kausbekova, Assiya Kussainova, Nurtas Kalibekov, Dulat Serikbaiuly, Rakhmetkazhi Bersimbaev

Open access · goldAbstract read
In one paragraph

Article in Asian Pacific journal of cancer prevention : APJCP, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Mechanisms and markers of lung ageing in health and disease.European respiratory review : an official journal of the European Respiratory Society · 2025
    Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Olga BulgakovaL.N.Gumilyov Eurasian National University Institute of Cell Biology and Biotechnology, Nur-Sultan, Kazakhstan.
Asemgul KausbekovaL.N.Gumilyov Eurasian National University Institute of Cell Biology and Biotechnology, Nur-Sultan, Kazakhstan.
Assiya KussainovaL.N.Gumilyov Eurasian National University Institute of Cell Biology and Biotechnology, Nur-Sultan, Kazakhstan.
Nurtas KalibekovNational Research Oncology Center, Nur-Sultan, Kazakhstan.
Dulat SerikbaiulyNational Research Oncology Center, Nur-Sultan, Kazakhstan.
Rakhmetkazhi BersimbaevL.N.Gumilyov Eurasian National University Institute of Cell Biology and Biotechnology, Nur-Sultan, Kazakhstan.
National Research Center for Maternal and Child Health · KZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveCirculating cell-free mitochondrial DNA (cf-MtDNA) has been reported in patients with chronic obstructive pulmonary disease (COPD) and lung cancers. However, inter-relationships among the three biological events have not been well-characterized. Therefore, our investigation was conducted to better understand the role of cf-MtDNA on pathogenesis of the two diseases.

methodsPlasma samples were collected from 64 non-small cell lung cancer (NSCLC) patients (before therapy), 45 patients with COPD and 62 healthy individuals. cf-MtDNA copy numbers were detected using quantitative real-time polymerase chain reaction (qRT-PCR) and cytokines were determined using a human ELISA kit.

resultsOur data indicate that smoking statuses of the patients and controls were significantly associated with increased cf-MtDNA in plasma samples. Furthermore, NSCLC patients had significantly higher cf-MtDNA copy numbers than COPD patients (p < 0.03) and normal controls (p < 0.02), together with elevated proinflammatory cytokines over the controls (p < 0.05). Our  study shows that the copy numbers for the NSCLC patients were positively associated with their subsequent metastasis but inversely associated with their overall survival.  Conclusion: Our study indicates certain lung injury (e.g., from cigarette smoking) was responsible for the release of cf-MtDNA and proinflammatory cytokines into plasmas among our patients and controls. The increase in cf-MtDNA copy numbers was significantly associated with the development of both COPD and NSCLC, with increase in interleukin 6, and from our 5-year follow-up, with poor prognosis among the NSCLC patients. Therefore, with further validation, cf-MtDNA can be considered for use as diagnostic and prognostic biomarkers for NSCLC.

Indexed as

BiomarkersCarcinoma, Non-Small-Cell LungCase-Control StudiesCell-Free Nucleic AcidsCytokinesDNA, MitochondrialFemaleHumansLung NeoplasmsMaleMiddle AgedPulmonary Disease, Chronic ObstructiveBiomarkersCell-Free Nucleic AcidsCytokinesDNA, Mitochondrialchronic obstructive pulmonary diseasecirculating cell-free mitochondrial DNAdiagnostic and prognostic biomarkersInterleukin-6Lung cancer

Identifiers

PMID34181353
PMCPMC8418868
OpenAlexW3173337040

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.